A carregar...
Engineering better chimeric antigen receptor T cells
CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relap...
Na minha lista:
| Publicado no: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7709221/ https://ncbi.nlm.nih.gov/pubmed/33292660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00190-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|